2024
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer
Chen W, Ballman K, Partridge A, Hahn O, Briccetti F, Irvin W, Symington B, Visvanathan K, Pohlmann P, Openshaw T, Weiss A, Winer E, Carey L, Holmes M. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA 2024, 331: 1714-1721. PMID: 38683596, PMCID: PMC11059055, DOI: 10.1001/jama.2024.4840.Peer-Reviewed Original ResearchSurvivors of breast cancerInvasive disease-free survival eventsDisease-free survival eventsNonmetastatic breast cancerBreast cancer recurrenceBreast cancerFollow-upRisk of breast cancer recurrenceHazard ratioInvasive cancer eventOverall survivalPrevent breast cancer recurrenceCancer recurrenceBreast cancer survivalInvasive disease-free survivalRates of grade 3Adjuvant breast cancer treatmentTrial of aspirinSurvival eventsDisease-free survivalMedian Follow-UpDouble-blind trialDaily aspirin therapyStudies of aspirinBreast cancer treatment
2023
Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival
Wang Z, Katsaros D, Wang J, Biglio N, Hernandez B, Fei P, Lu L, Risch H, Yu H. Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival. Scientific Reports 2023, 13: 18962. PMID: 37923775, PMCID: PMC10624674, DOI: 10.1038/s41598-023-45932-4.Peer-Reviewed Original ResearchConceptsImmune cell clustersT cellsHost immunityImmune cellsUnsupervised hierarchical clusteringImmune responseCD8-positive T cellsMemory CD4 T cellsCox regression survival analysisRegulatory T cellsPositive T cellsCD4 T cellsDifferent immune cellsDistinct immune responsesBreast cancer survivalImmune cell subtypesMemory B cellsImmune cell typesRegression survival analysisCell clustersBreast cancer progressionT cell receptor signalingCytokine stormOverall survivalFavorable survivalRace, geography, and risk of breast cancer treatment delays: A population‐based study 2004–2015
Reeder‐Hayes K, Jackson B, Baggett C, Kuo T, Gaddy J, LeBlanc M, Bell E, Green L, Wheeler S. Race, geography, and risk of breast cancer treatment delays: A population‐based study 2004–2015. Cancer 2023, 129: 925-933. PMID: 36683417, PMCID: PMC11578059, DOI: 10.1002/cncr.34573.Peer-Reviewed Original ResearchConceptsBreast cancer treatment delaysTreatment delayMagnitude of racial disparitiesNon-black patientsStage I-III breast cancerI-III breast cancerPoor-quality carePopulation health resourcesRisk of treatment delayBlack patientsBreast cancer survivalCancer treatment delayPopulation-based studyDiagnosis to first treatmentAssociated with riskBreast cancerCancer RegistryObservational cohort of patientsTreatment delay >Health resourcesPopulation-basedPoisson regressionCancer survivalSociodemographic dataRacial disparities
2022
Adipose tissue radiodensity and mortality among patients with nonmetastatic breast cancer
Cheng E, Caan BJ, Chen WY, Irwin ML, Prado CM, Cespedes Feliciano EM. Adipose tissue radiodensity and mortality among patients with nonmetastatic breast cancer. Clinical Nutrition 2022, 41: 2607-2613. PMID: 36306565, PMCID: PMC9722634, DOI: 10.1016/j.clnu.2022.09.016.Peer-Reviewed Original ResearchConceptsNonmetastatic breast cancerVisceral adipose tissueBreast cancerBreast cancer prognosisOverall mortalitySpecific mortalityAdipose tissueCancer prognosisTissue radiodensityMultivariable Cox proportional hazards regressionKaiser Permanente Northern CaliforniaCox proportional hazards regressionRole of adiposityBody mass indexProportional hazards regressionBreast cancer survivalNovel prognostic markerThird lumbar vertebraIntegrated healthcare systemNon-Hispanic whitesMultiple cancer typesHazard ratioNonmetastatic patientsPrognostic factorsClinicopathological characteristicsSocioeconomic disparities in supportive therapy use and tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer.
Kier M, Li Z, Casasanta N, Patel R, Agarwal P, Zimmerman B, Yang Y, Fink M, Zhou X, Newman S, Chen R, Schadt E, Oh W, Tiersten A. Socioeconomic disparities in supportive therapy use and tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer. Journal Of Clinical Oncology 2022, 40: 523-523. DOI: 10.1200/jco.2022.40.16_suppl.523.Peer-Reviewed Original ResearchRate of discontinuationSupportive therapyBreast cancerAI therapyDiscontinuation ratesSocioeconomic disparitiesInsurance coverageEarly-stage hormone receptor-positive breast cancerSide effectsExact testHormone receptor-positive breast cancerAdjuvant aromatase inhibitor therapyReceptor-positive breast cancerHormone-positive breast cancerInitial AI therapyAromatase inhibitor therapyRetrospective chart reviewMajority of patientsPositive breast cancerBreast cancer survivalFisher's exact testLow socioeconomic statusAdjuvant AIPrimary languageEarly discontinuationA randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial
Chen W, Ballman K, Winer E, Openshaw T, Hahn O, Briccetti F, Irvin W, Pohlmann P, Carey L, Partridge A, Weiss A, McCall L, Matyka C, Carvan M, Holmes M. A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial. Journal Of Clinical Oncology 2022, 40: 360922-360922. DOI: 10.1200/jco.2022.40.36_suppl.360922.Peer-Reviewed Original ResearchInvasive disease-free survivalHER2-negative breast cancerStratified hazard ratioDisease-free survivalHazard ratioBreast cancerIDFS eventsAspirin usersCardiovascular diseaseGrade 3/4 adverse eventsAspirin/non-steroidal anti-inflammatory drugsNon-steroidal anti-inflammatory drugsAdjuvant aspirin therapyRandomized phase IIIRegular aspirin usersPlacebo-controlled trialDouble-blinded fashionBreast cancer survivorsBody mass indexBreast cancer trialsBreast cancer survivalBreast cancer recurrenceMultiple epidemiologic studiesAnti-inflammatory drugsAnti-tumor effectsFertility Preservation in Breast Cancer Patients
Marin L, Turan V, Oktay K. Fertility Preservation in Breast Cancer Patients. 2022, 185-198. DOI: 10.1007/978-3-030-47767-7_14.Peer-Reviewed Original ResearchFertility preservation issuesBreast cancerGonadotropin-releasing hormone agonistNovel chemotherapy regimensSafety of pregnancyFertility preservation techniquesBreast cancer survivorsBreast cancer patientsBreast cancer survivalPremature ovarian insufficiencyBreast cancer treatmentChemotherapy regimensOvarian suppressionPremenopausal womenOvarian reserveHormone agonistCancer survivorsCommon malignancyFertility preservationOvarian functionCancer patientsCancer survivalBRCA mutationsSexual dysfunctionFertility risks
2021
Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival
Li W, Amei A, Bui F, Norouzifar S, Lu L, Wang Z. Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival. Cancers 2021, 13: 2879. PMID: 34207556, PMCID: PMC8228363, DOI: 10.3390/cancers13122879.Peer-Reviewed Original ResearchT cell activationNeoantigen expressionChi-squared testOverall survivalBreast cancerMultivariable Cox proportional hazards modelsMultivariable Cox regression modelsCox proportional hazards modelImproved overall survivalT-cell statusT cell exhaustionBreast cancer patientsKaplan-Meier survivalBreast cancer survivalCox regression modelClinical-pathological variablesReceptor-positive subgroupCancer immunotherapy efficacyProportional hazards modelPearson's chi-squared testTumor-specific somatic mutationsSpearman correlation analysisImmunotherapy efficacyPathological variablesPatient survival
2020
ABC trial (A011502): A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy breast cancer.
Chen W, Winer E, Ballman K, Partridge A, Carey L, Carvan M, Matyka C, Openshaw T, Visvanathan K, Symington B, Holmes M. ABC trial (A011502): A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy breast cancer. Journal Of Clinical Oncology 2020, 38: tps600-tps600. DOI: 10.1200/jco.2020.38.15_suppl.tps600.Peer-Reviewed Original ResearchInvasive disease-free survivalAspirin usersCardiovascular diseaseBreast cancerHER2-negative breast cancer patientsBlinded placebo-controlled trialHER2-negative breast cancerNegative breast cancer patientsRandomized phase IIIRegular aspirin usersPlacebo-controlled trialDisease-free survivalHormone receptor statusDouble-blinded fashionMonths of diagnosisBreast cancer survivorsTime of presentationBody mass indexBreast cancer patientsTherapy-Breast CancerBreast cancer survivalMultiple epidemiologic studiesNegative breast cancerAnti-tumor effectsDaily aspirin
2019
Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer
Usiskin I, Li F, Irwin ML, Cartmel B, Sanft T. Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer. Breast Cancer 2019, 26: 719-728. PMID: 31119682, DOI: 10.1007/s12282-019-00974-3.Peer-Reviewed Original ResearchConceptsPathologic complete responseChemotherapy completionComplete responseNeoadjuvant chemotherapyLower BMIResidual diseaseBreast cancerPhysical activityNeoadjuvant breast cancer treatmentRetrospective case-control studyUnconditional logistic regression modelsCompletion of chemotherapyMedical record reviewBreast cancer survivalLower mean BMICase-control studyPhysical activity 1Breast cancer treatmentLogistic regression modelsBreast cancer diagnosisMean BMIPatient characteristicsRecord reviewPurposePhysical activityCancer survivalABC trial (A011502): A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer.
Chen W, Winer E, Ballman K, Partridge A, Carey L, Carvan M, Matyka C, Visvanathan K, Symington B, Holmes M. ABC trial (A011502): A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer. Journal Of Clinical Oncology 2019, 37: tps599-tps599. DOI: 10.1200/jco.2019.37.15_suppl.tps599.Peer-Reviewed Original ResearchInvasive disease-free survivalAspirin usersCardiovascular diseaseBreast cancerHER2-negative breast cancer patientsHER2-negative breast cancerNegative breast cancer patientsRandomized phase IIIRegular aspirin usersTrial of aspirinDisease-free survivalHormone receptor statusDouble-blinded fashionMonths of diagnosisBreast cancer survivorsTime of presentationBody mass indexBreast cancer patientsTherapy-Breast CancerBreast cancer survivalMultiple epidemiologic studiesNegative breast cancerAnti-tumor effectsDaily aspirinIDFS events
2018
Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses’ Health Studies
Kensler KH, Poole EM, Heng YJ, Collins LC, Glass B, Beck AH, Hazra A, Rosner BA, Eliassen AH, Hankinson SE, Winer EP, Brown M, Tamimi RM. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses’ Health Studies. Journal Of The National Cancer Institute 2018, 111: 700-708. PMID: 30445651, PMCID: PMC6624168, DOI: 10.1093/jnci/djy173.Peer-Reviewed Original ResearchConceptsBreast cancer mortalityHealth Study II cohortNurses' Health StudyAR protein expressionCancer mortalityBreast cancerLog-linear associationAR expressionHealth StudyAndrogen receptorER- cancersHazard ratioNurses' Health Study II cohortCox proportional hazards modelProtein expressionInvasive breast cancerAndrogen receptor expressionBreast cancer survivalConfidence intervalsProportional hazards modelHormone receptor signalingPostmenopausal womenNegative tumorsWorse prognosisYears postdiagnosisAssociation between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database
Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Research And Treatment 2018, 173: 209-216. PMID: 30242577, DOI: 10.1007/s10549-018-4968-7.Peer-Reviewed Original ResearchConceptsMetastatic-free intervalMetastatic breast cancerInitial breast cancer diagnosisBreast cancer-specific mortalityCancer-specific mortalitySubsequent metastatic diseaseBreast cancer diagnosisMetastatic diseaseFree intervalBreast cancerCancer diagnosisBreast cancer-specific survival ratesMetastatic breast cancer survivalCancer-specific survival ratesDiagnosis of MBCImproved cancer-specific survivalRecurrent metastatic breast cancerCancer-specific survivalEnd Results (SEER) databaseLow tumor gradeBreast cancer survivalChoice of treatmentStratification of patientsMethodsThe SurveillancePurposeThe prevalenceAssociation between metastatic free interval and recurrent metastatic breast cancer survival: Findings from the Surveillance, Epidemiology and End Results database.
Chang E, Mougalian S, Adelson K, Young M, Yu J. Association between metastatic free interval and recurrent metastatic breast cancer survival: Findings from the Surveillance, Epidemiology and End Results database. Journal Of Clinical Oncology 2018, 36: e13069-e13069. DOI: 10.1200/jco.2018.36.15_suppl.e13069.Peer-Reviewed Original Research
2017
ABC trial (A011502): A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer.
Chen W, Winer E, Barry W, Hudis C, Openshaw T, Visvanathan K, Symington B, Matyka C, Holmes M. ABC trial (A011502): A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer. Journal Of Clinical Oncology 2017, 35: tps586-tps586. DOI: 10.1200/jco.2017.35.15_suppl.tps586.Peer-Reviewed Original ResearchAspirin usersRegular aspirin usersBreast cancer survivalMultiple epidemiologic studiesAnti-tumor activityMetastatic adenocarcinomaRandomized trialsDecreased riskCancer survivalCardiovascular diseaseMetastatic cancerEpidemiologic studiesAvailable drugsVivo evidenceAspirinMultiple pathwaysAdenocarcinomaCancerDiseaseTrials
2016
Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival
Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM. Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. Journal Of Clinical Oncology 2016, 34: 3308-3314. PMID: 27480155, DOI: 10.1200/jco.2015.65.8013.Peer-Reviewed Original ResearchConceptsMultivariable Cox proportional hazards modelsCox proportional hazards modelBreast cancer deathsProportional hazards modelBreast cancerYears of ageYounger ageCancer deathHazards modelHuman epidermal growth factor receptor 2 subtypeStage INational Comprehensive Cancer Network centersBreast cancer-specific survivalEarly-stage breast cancerYoung womenCancer-specific survivalSurvival of womenEarly breast cancerLuminal B tumorsBreast cancer mortalityTriple-negative tumorsBreast cancer survivalLuminal breast cancerBreast cancer recurrenceBreast cancer subtypesDietary Intake of Isoflavone and All‐Cause Mortality in Women with Breast Cancer: the Breast Cancer Family Registry
Haslam D, John E, Terry M, Knight J, Andrulis I, Daly M, Buys S, Zhang F. Dietary Intake of Isoflavone and All‐Cause Mortality in Women with Breast Cancer: the Breast Cancer Family Registry. The FASEB Journal 2016, 30 DOI: 10.1096/fasebj.30.1_supplement.902.8.Peer-Reviewed Original ResearchBreast Cancer Family RegistryBody mass indexCancer Family RegistryCause mortalityDietary intakeBreast cancerFamily RegistryPhysical activityRace/ethnicityHormonal therapyNormal weightMass indexFirst primary invasive breast cancerPrimary invasive breast cancerTumor estrogen receptor statusHealth Eating IndexTumor hormone receptorsDrinks/weekFood frequency questionnaireInvasive breast cancerEstrogen receptor statusPost-menopausal womenTotal fiber intakeBreast cancer survivalHigh dietary intake
2015
Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors
Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. Journal Of Clinical Oncology 2015, 33: 2254-2261. PMID: 25964252, PMCID: PMC4486344, DOI: 10.1200/jco.2014.57.1349.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAsianBiomarkers, TumorBlack or African AmericanBody Mass IndexBreast NeoplasmsCause of DeathDisease-Free SurvivalEthnicityFemaleHealth Status DisparitiesHealthcare DisparitiesHispanic or LatinoHumansLogistic ModelsMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm StagingProportional Hazards ModelsRacial GroupsRisk FactorsSocioeconomic FactorsTime FactorsTreatment OutcomeTriple Negative Breast NeoplasmsUnited StatesWhite PeopleConceptsBreast cancer-specific survivalEstrogen receptor-positive tumorsCancer-specific survivalReceptor-positive tumorsBreast cancer survivalTumor characteristicsCancer survivalBreast cancerNational Comprehensive Cancer Network centersBreast cancer-specific deathHuman epidermal growth factor receptorCancer-specific deathMultivariable adjusted modelsYear of diagnosisBody mass indexProportional hazards regressionEpidermal growth factor receptorRace/ethnicityGrowth factor receptorHazards regressionMass indexRisk factorsSurvival differencesLike tumorsHigh riskCirculating tumor cell clusters-associated gene plakoglobin and breast cancer survival
Lu L, Zeng H, Gu X, Ma W. Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival. Breast Cancer Research And Treatment 2015, 151: 491-500. PMID: 25957595, DOI: 10.1007/s10549-015-3416-1.Peer-Reviewed Original ResearchConceptsBreast cancer survivalCancer survivalBreast cancerTumor cellsDisease-specific deathBreast cancer recurrencePotential prognostic biomarkerBreast cancer metastasisEpithelial-mesenchymal transitionHigh metastatic potentialFurther metastasesPatient survivalCancer recurrencePrognostic biomarkerTherapeutic targetSurvival analysisMetastatic potentialCancer metastasisMajor causeHigh expressionEpithelial cellsCancerRole of plakoglobinDouble-edged functionSurvival
2011
Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1
Zeng H, Irwin ML, Lu L, Risch H, Mayne S, Mu L, Deng Q, Scarampi L, Mitidieri M, Katsaros D, Yu H. Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1. Breast Cancer Research And Treatment 2011, 133: 127-135. PMID: 21837478, DOI: 10.1007/s10549-011-1716-7.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChromosomal Proteins, Non-HistoneDNA MethylationEpigenesis, GeneticFemaleGene ExpressionGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansKaplan-Meier EstimateMotor ActivityRepressor ProteinsTumor Suppressor ProteinsConceptsBreast cancer patientsBreast cancer survivalCancer patientsPhysical activityOverall survivalSurvival outcomesTumor suppressor geneCancer survivalHormone receptor-positive tumorsModerate-intensity aerobic exerciseHigh expressionBreast cancer deathsReceptor-positive tumorsRandomized clinical trialsExercise-related changesSuppressor genePeripheral blood leukocytesBreast cancer diagnosisGene expressionDisease recurrenceAerobic exerciseCancer deathClinical trialsTumor featuresBlood leukocytes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply